Astrana Health, Inc. (ASTH) Stock Competitors & Peer Comparison
See (ASTH) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ASTH | $38.38 | +0.00% | 1.9B | 62.92 | $0.61 | N/A |
| HCA | $396.93 | +1.78% | 88.1B | 13.67 | $29.04 | +0.76% |
| THC | $183.56 | +2.48% | 15.8B | 9.55 | $19.24 | N/A |
| DVA | $208.98 | -0.37% | 13.4B | 20.15 | $10.37 | N/A |
| SOLV | $76.56 | -0.44% | 13.3B | 9.37 | $8.17 | N/A |
| FMS | $23.75 | +1.28% | 12.8B | 12.57 | $1.89 | +3.65% |
| EHC | $99.84 | +0.48% | 9.9B | 17.10 | $5.84 | +0.74% |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
| UHS | $146.90 | +0.64% | 9.2B | 6.14 | $23.95 | +0.54% |
| ENSG | $156.93 | +4.13% | 9.2B | 25.60 | $6.13 | +0.16% |
Stock Comparison
ASTH vs HCA Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, HCA has a market cap of 88.1B. Regarding current trading prices, ASTH is priced at $38.38, while HCA trades at $396.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas HCA's P/E ratio is 13.67. In terms of profitability, ASTH's ROE is +0.04%, compared to HCA's ROE of -1.23%. Regarding short-term risk, ASTH and HCA have similar daily volatility (2.39).Check HCA's competition here
ASTH vs THC Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, THC has a market cap of 15.8B. Regarding current trading prices, ASTH is priced at $38.38, while THC trades at $183.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas THC's P/E ratio is 9.55. In terms of profitability, ASTH's ROE is +0.04%, compared to THC's ROE of +0.41%. Regarding short-term risk, ASTH is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check THC's competition here
ASTH vs DVA Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, DVA has a market cap of 13.4B. Regarding current trading prices, ASTH is priced at $38.38, while DVA trades at $208.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas DVA's P/E ratio is 20.15. In terms of profitability, ASTH's ROE is +0.04%, compared to DVA's ROE of -1.33%. Regarding short-term risk, ASTH is more volatile compared to DVA. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check DVA's competition here
ASTH vs SOLV Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, SOLV has a market cap of 13.3B. Regarding current trading prices, ASTH is priced at $38.38, while SOLV trades at $76.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas SOLV's P/E ratio is 9.37. In terms of profitability, ASTH's ROE is +0.04%, compared to SOLV's ROE of +0.31%. Regarding short-term risk, ASTH is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check SOLV's competition here
ASTH vs FMS Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, FMS has a market cap of 12.8B. Regarding current trading prices, ASTH is priced at $38.38, while FMS trades at $23.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas FMS's P/E ratio is 12.57. In terms of profitability, ASTH's ROE is +0.04%, compared to FMS's ROE of +0.07%. Regarding short-term risk, ASTH is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check FMS's competition here
ASTH vs EHC Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, EHC has a market cap of 9.9B. Regarding current trading prices, ASTH is priced at $38.38, while EHC trades at $99.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas EHC's P/E ratio is 17.10. In terms of profitability, ASTH's ROE is +0.04%, compared to EHC's ROE of +0.25%. Regarding short-term risk, ASTH is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check EHC's competition here
ASTH vs OSH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, ASTH is priced at $38.38, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas OSH's P/E ratio is -17.65. In terms of profitability, ASTH's ROE is +0.04%, compared to OSH's ROE of +4.64%. Regarding short-term risk, ASTH is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check OSH's competition here
ASTH vs UHS Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, UHS has a market cap of 9.2B. Regarding current trading prices, ASTH is priced at $38.38, while UHS trades at $146.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas UHS's P/E ratio is 6.14. In terms of profitability, ASTH's ROE is +0.04%, compared to UHS's ROE of +0.21%. Regarding short-term risk, ASTH is more volatile compared to UHS. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check UHS's competition here
ASTH vs ENSG Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, ENSG has a market cap of 9.2B. Regarding current trading prices, ASTH is priced at $38.38, while ENSG trades at $156.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas ENSG's P/E ratio is 25.60. In terms of profitability, ASTH's ROE is +0.04%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, ASTH is less volatile compared to ENSG. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check ENSG's competition here
ASTH vs CHE Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CHE has a market cap of 5.8B. Regarding current trading prices, ASTH is priced at $38.38, while CHE trades at $433.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CHE's P/E ratio is 23.68. In terms of profitability, ASTH's ROE is +0.04%, compared to CHE's ROE of +0.25%. Regarding short-term risk, ASTH is more volatile compared to CHE. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check CHE's competition here
ASTH vs LHCG Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, ASTH is priced at $38.38, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas LHCG's P/E ratio is 82.83. In terms of profitability, ASTH's ROE is +0.04%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, ASTH is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check LHCG's competition here
ASTH vs MMED Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, MMED has a market cap of 4.1B. Regarding current trading prices, ASTH is priced at $38.38, while MMED trades at $14.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas MMED's P/E ratio is -11.57. In terms of profitability, ASTH's ROE is +0.04%, compared to MMED's ROE of -0.09%. Regarding short-term risk, ASTH is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check MMED's competition here
ASTH vs OPCH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, OPCH has a market cap of 3.4B. Regarding current trading prices, ASTH is priced at $38.38, while OPCH trades at $21.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas OPCH's P/E ratio is 16.89. In terms of profitability, ASTH's ROE is +0.04%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, ASTH is more volatile compared to OPCH. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check OPCH's competition here
ASTH vs LFST Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, LFST has a market cap of 3.3B. Regarding current trading prices, ASTH is priced at $38.38, while LFST trades at $8.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas LFST's P/E ratio is 143.67. In terms of profitability, ASTH's ROE is +0.04%, compared to LFST's ROE of +0.02%. Regarding short-term risk, ASTH is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check LFST's competition here
ASTH vs AMED Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, ASTH is priced at $38.38, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AMED's P/E ratio is 39.30. In terms of profitability, ASTH's ROE is +0.04%, compared to AMED's ROE of +0.09%. Regarding short-term risk, ASTH is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check AMED's competition here
ASTH vs BKD Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, BKD has a market cap of 3.3B. Regarding current trading prices, ASTH is priced at $38.38, while BKD trades at $13.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas BKD's P/E ratio is -15.83. In terms of profitability, ASTH's ROE is +0.04%, compared to BKD's ROE of +401.19%. Regarding short-term risk, ASTH is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check BKD's competition here
ASTH vs NHC Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, NHC has a market cap of 3B. Regarding current trading prices, ASTH is priced at $38.38, while NHC trades at $191.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas NHC's P/E ratio is 24.22. In terms of profitability, ASTH's ROE is +0.04%, compared to NHC's ROE of +0.12%. Regarding short-term risk, ASTH is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check NHC's competition here
ASTH vs ACHC Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, ACHC has a market cap of 2.3B. Regarding current trading prices, ASTH is priced at $38.38, while ACHC trades at $24.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas ACHC's P/E ratio is -2.02. In terms of profitability, ASTH's ROE is +0.04%, compared to ACHC's ROE of -0.44%. Regarding short-term risk, ASTH is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check ACHC's competition here
ASTH vs SEM Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, SEM has a market cap of 2.1B. Regarding current trading prices, ASTH is priced at $38.38, while SEM trades at $16.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas SEM's P/E ratio is 15.52. In terms of profitability, ASTH's ROE is +0.04%, compared to SEM's ROE of +0.08%. Regarding short-term risk, ASTH is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check SEM's competition here
ASTH vs MD Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, MD has a market cap of 2B. Regarding current trading prices, ASTH is priced at $38.38, while MD trades at $24.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas MD's P/E ratio is 11.73. In terms of profitability, ASTH's ROE is +0.04%, compared to MD's ROE of +0.20%. Regarding short-term risk, ASTH is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check MD's competition here
ASTH vs SGRY Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, SGRY has a market cap of 2B. Regarding current trading prices, ASTH is priced at $38.38, while SGRY trades at $15.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas SGRY's P/E ratio is -25.66. In terms of profitability, ASTH's ROE is +0.04%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, ASTH is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check SGRY's competition here
ASTH vs AGL Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AGL has a market cap of 1.9B. Regarding current trading prices, ASTH is priced at $38.38, while AGL trades at $113.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AGL's P/E ratio is -5.01. In terms of profitability, ASTH's ROE is +0.04%, compared to AGL's ROE of -1.46%. Regarding short-term risk, ASTH is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AGL's competition here
ASTH vs AMEH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, ASTH is priced at $38.38, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AMEH's P/E ratio is 39.25. In terms of profitability, ASTH's ROE is +0.04%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, ASTH is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AMEH's competition here
ASTH vs ADUS Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, ADUS has a market cap of 1.8B. Regarding current trading prices, ASTH is priced at $38.38, while ADUS trades at $94.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas ADUS's P/E ratio is 17.47. In terms of profitability, ASTH's ROE is +0.04%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, ASTH is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check ADUS's competition here
ASTH vs AVAH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AVAH has a market cap of 1.6B. Regarding current trading prices, ASTH is priced at $38.38, while AVAH trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AVAH's P/E ratio is 6.21. In terms of profitability, ASTH's ROE is +0.04%, compared to AVAH's ROE of +2.41%. Regarding short-term risk, ASTH is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AVAH's competition here
ASTH vs HCSG Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, HCSG has a market cap of 1.5B. Regarding current trading prices, ASTH is priced at $38.38, while HCSG trades at $22.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas HCSG's P/E ratio is 23.75. In terms of profitability, ASTH's ROE is +0.04%, compared to HCSG's ROE of +0.14%. Regarding short-term risk, ASTH is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check HCSG's competition here
ASTH vs ARDT Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, ASTH is priced at $38.38, while ARDT trades at $9.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas ARDT's P/E ratio is 9.76. In terms of profitability, ASTH's ROE is +0.04%, compared to ARDT's ROE of +0.09%. Regarding short-term risk, ASTH is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check ARDT's competition here
ASTH vs INNV Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, INNV has a market cap of 1.3B. Regarding current trading prices, ASTH is priced at $38.38, while INNV trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas INNV's P/E ratio is -116.00. In terms of profitability, ASTH's ROE is +0.04%, compared to INNV's ROE of -0.09%. Regarding short-term risk, ASTH is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check INNV's competition here
ASTH vs AMN Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AMN has a market cap of 1.2B. Regarding current trading prices, ASTH is priced at $38.38, while AMN trades at $31.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AMN's P/E ratio is -37.05. In terms of profitability, ASTH's ROE is +0.04%, compared to AMN's ROE of -0.05%. Regarding short-term risk, ASTH is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AMN's competition here
ASTH vs BKDT Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, ASTH is priced at $38.38, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas BKDT's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to BKDT's ROE of +401.19%. Regarding short-term risk, ASTH is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check BKDT's competition here
ASTH vs PNTG Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, PNTG has a market cap of 1.2B. Regarding current trading prices, ASTH is priced at $38.38, while PNTG trades at $33.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas PNTG's P/E ratio is 39.40. In terms of profitability, ASTH's ROE is +0.04%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, ASTH is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check PNTG's competition here
ASTH vs CMPS Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CMPS has a market cap of 1.1B. Regarding current trading prices, ASTH is priced at $38.38, while CMPS trades at $11.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CMPS's P/E ratio is -3.75. In terms of profitability, ASTH's ROE is +0.04%, compared to CMPS's ROE of -1.51%. Regarding short-term risk, ASTH is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check CMPS's competition here
ASTH vs USPH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, USPH has a market cap of 1B. Regarding current trading prices, ASTH is priced at $38.38, while USPH trades at $66.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas USPH's P/E ratio is 132.72. In terms of profitability, ASTH's ROE is +0.04%, compared to USPH's ROE of +0.00%. Regarding short-term risk, ASTH is more volatile compared to USPH. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check USPH's competition here
ASTH vs TALK Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, TALK has a market cap of 871.1M. Regarding current trading prices, ASTH is priced at $38.38, while TALK trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas TALK's P/E ratio is 130.00. In terms of profitability, ASTH's ROE is +0.04%, compared to TALK's ROE of +0.01%. Regarding short-term risk, ASTH is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check TALK's competition here
ASTH vs FSHCX Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, FSHCX has a market cap of 807.3M. Regarding current trading prices, ASTH is priced at $38.38, while FSHCX trades at $113.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas FSHCX's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to FSHCX's ROE of N/A. Regarding short-term risk, ASTH is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check FSHCX's competition here
ASTH vs TALKW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, TALKW has a market cap of 791.9M. Regarding current trading prices, ASTH is priced at $38.38, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas TALKW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to TALKW's ROE of +0.01%. Regarding short-term risk, ASTH is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check TALKW's competition here
ASTH vs EHAB Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, EHAB has a market cap of 706.9M. Regarding current trading prices, ASTH is priced at $38.38, while EHAB trades at $13.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas EHAB's P/E ratio is -197.14. In terms of profitability, ASTH's ROE is +0.04%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, ASTH is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check EHAB's competition here
ASTH vs SNDA Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, SNDA has a market cap of 697.2M. Regarding current trading prices, ASTH is priced at $38.38, while SNDA trades at $34.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas SNDA's P/E ratio is -5.97. In terms of profitability, ASTH's ROE is +0.04%, compared to SNDA's ROE of -0.35%. Regarding short-term risk, ASTH is more volatile compared to SNDA. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check SNDA's competition here
ASTH vs GMRS Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, GMRS has a market cap of 547M. Regarding current trading prices, ASTH is priced at $38.38, while GMRS trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas GMRS's P/E ratio is 6.21. In terms of profitability, ASTH's ROE is +0.04%, compared to GMRS's ROE of N/A. Regarding short-term risk, ASTH is less volatile compared to GMRS. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check GMRS's competition here
ASTH vs TOI Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, TOI has a market cap of 509.9M. Regarding current trading prices, ASTH is priced at $38.38, while TOI trades at $5.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas TOI's P/E ratio is -14.57. In terms of profitability, ASTH's ROE is +0.04%, compared to TOI's ROE of +3.27%. Regarding short-term risk, ASTH is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check TOI's competition here
ASTH vs MCTA Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, ASTH is priced at $38.38, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas MCTA's P/E ratio is 419.36. In terms of profitability, ASTH's ROE is +0.04%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, ASTH is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check MCTA's competition here
ASTH vs CYH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CYH has a market cap of 441.8M. Regarding current trading prices, ASTH is priced at $38.38, while CYH trades at $3.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CYH's P/E ratio is 0.91. In terms of profitability, ASTH's ROE is +0.04%, compared to CYH's ROE of +0.06%. Regarding short-term risk, ASTH is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check CYH's competition here
ASTH vs CCRN Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CCRN has a market cap of 435M. Regarding current trading prices, ASTH is priced at $38.38, while CCRN trades at $13.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CCRN's P/E ratio is -4.32. In terms of profitability, ASTH's ROE is +0.04%, compared to CCRN's ROE of -0.27%. Regarding short-term risk, ASTH is more volatile compared to CCRN. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check CCRN's competition here
ASTH vs AUNA Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AUNA has a market cap of 390.8M. Regarding current trading prices, ASTH is priced at $38.38, while AUNA trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AUNA's P/E ratio is 19.56. In terms of profitability, ASTH's ROE is +0.04%, compared to AUNA's ROE of +0.04%. Regarding short-term risk, ASTH is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AUNA's competition here
ASTH vs AIRS Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AIRS has a market cap of 354.8M. Regarding current trading prices, ASTH is priced at $38.38, while AIRS trades at $5.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AIRS's P/E ratio is -29.59. In terms of profitability, ASTH's ROE is +0.04%, compared to AIRS's ROE of -0.12%. Regarding short-term risk, ASTH is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AIRS's competition here
ASTH vs CSU Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, ASTH is priced at $38.38, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CSU's P/E ratio is 0.67. In terms of profitability, ASTH's ROE is +0.04%, compared to CSU's ROE of -0.51%. Regarding short-term risk, ASTH is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check CSU's competition here
ASTH vs JYNT Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, JYNT has a market cap of 131.7M. Regarding current trading prices, ASTH is priced at $38.38, while JYNT trades at $9.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas JYNT's P/E ratio is 102.67. In terms of profitability, ASTH's ROE is +0.04%, compared to JYNT's ROE of +0.17%. Regarding short-term risk, ASTH is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check JYNT's competition here
ASTH vs NAKAW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, ASTH is priced at $38.38, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas NAKAW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to NAKAW's ROE of -0.85%. Regarding short-term risk, ASTH is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check NAKAW's competition here
ASTH vs FVE Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, ASTH is priced at $38.38, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas FVE's P/E ratio is -5.64. In terms of profitability, ASTH's ROE is +0.04%, compared to FVE's ROE of -0.15%. Regarding short-term risk, ASTH is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check FVE's competition here
ASTH vs BTMD Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, BTMD has a market cap of 96.6M. Regarding current trading prices, ASTH is priced at $38.38, while BTMD trades at $2.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas BTMD's P/E ratio is 5.09. In terms of profitability, ASTH's ROE is +0.04%, compared to BTMD's ROE of -0.23%. Regarding short-term risk, ASTH is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check BTMD's competition here
ASTH vs KDLYW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, ASTH is priced at $38.38, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas KDLYW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to KDLYW's ROE of -0.85%. Regarding short-term risk, ASTH is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check KDLYW's competition here
ASTH vs DCGO Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, DCGO has a market cap of 57.3M. Regarding current trading prices, ASTH is priced at $38.38, while DCGO trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas DCGO's P/E ratio is -0.31. In terms of profitability, ASTH's ROE is +0.04%, compared to DCGO's ROE of -0.89%. Regarding short-term risk, ASTH is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check DCGO's competition here
ASTH vs ALR Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, ASTH is priced at $38.38, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas ALR's P/E ratio is -1.11. In terms of profitability, ASTH's ROE is +0.04%, compared to ALR's ROE of -0.15%. Regarding short-term risk, ASTH is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check ALR's competition here
ASTH vs PIII Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, PIII has a market cap of 38M. Regarding current trading prices, ASTH is priced at $38.38, while PIII trades at $11.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas PIII's P/E ratio is -0.30. In terms of profitability, ASTH's ROE is +0.04%, compared to PIII's ROE of +1.85%. Regarding short-term risk, ASTH is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check PIII's competition here
ASTH vs PIIIW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, PIIIW has a market cap of 33.1M. Regarding current trading prices, ASTH is priced at $38.38, while PIIIW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas PIIIW's P/E ratio is -0.01. In terms of profitability, ASTH's ROE is +0.04%, compared to PIIIW's ROE of +1.85%. Regarding short-term risk, ASTH is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check PIIIW's competition here
ASTH vs IMAC Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, ASTH is priced at $38.38, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas IMAC's P/E ratio is -2.27. In terms of profitability, ASTH's ROE is +0.04%, compared to IMAC's ROE of +5.81%. Regarding short-term risk, ASTH is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check IMAC's competition here
ASTH vs CCEL Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CCEL has a market cap of 28.8M. Regarding current trading prices, ASTH is priced at $38.38, while CCEL trades at $3.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CCEL's P/E ratio is -11.19. In terms of profitability, ASTH's ROE is +0.04%, compared to CCEL's ROE of +0.16%. Regarding short-term risk, ASTH is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check CCEL's competition here
ASTH vs CANO-WT Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, ASTH is priced at $38.38, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, ASTH is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check CANO-WT's competition here
ASTH vs AIH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, ASTH is priced at $38.38, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AIH's P/E ratio is -2.78. In terms of profitability, ASTH's ROE is +0.04%, compared to AIH's ROE of +1.16%. Regarding short-term risk, ASTH is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AIH's competition here
ASTH vs CANO Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, ASTH is priced at $38.38, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CANO's P/E ratio is -0.01. In terms of profitability, ASTH's ROE is +0.04%, compared to CANO's ROE of -1.49%. Regarding short-term risk, ASTH is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check CANO's competition here
ASTH vs FTRP Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, ASTH is priced at $38.38, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas FTRP's P/E ratio is -1.22. In terms of profitability, ASTH's ROE is +0.04%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, ASTH is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check FTRP's competition here
ASTH vs AMS Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AMS has a market cap of 9.5M. Regarding current trading prices, ASTH is priced at $38.38, while AMS trades at $1.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AMS's P/E ratio is -6.50. In terms of profitability, ASTH's ROE is +0.04%, compared to AMS's ROE of -0.06%. Regarding short-term risk, ASTH is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AMS's competition here
ASTH vs MODV Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, ASTH is priced at $38.38, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas MODV's P/E ratio is -0.03. In terms of profitability, ASTH's ROE is +0.04%, compared to MODV's ROE of +1.84%. Regarding short-term risk, ASTH is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check MODV's competition here
ASTH vs GBNH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, ASTH is priced at $38.38, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas GBNH's P/E ratio is -0.06. In terms of profitability, ASTH's ROE is +0.04%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, ASTH is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check GBNH's competition here
ASTH vs RHE Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, ASTH is priced at $38.38, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas RHE's P/E ratio is -1.79. In terms of profitability, ASTH's ROE is +0.04%, compared to RHE's ROE of -0.36%. Regarding short-term risk, ASTH is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check RHE's competition here
ASTH vs RHE-PA Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, ASTH is priced at $38.38, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, ASTH's ROE is +0.04%, compared to RHE-PA's ROE of +2.11%. Regarding short-term risk, ASTH is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check RHE-PA's competition here
ASTH vs TOIIW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, TOIIW has a market cap of 4.4M. Regarding current trading prices, ASTH is priced at $38.38, while TOIIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas TOIIW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to TOIIW's ROE of +3.27%. Regarding short-term risk, ASTH is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check TOIIW's competition here
ASTH vs IMACW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, ASTH is priced at $38.38, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas IMACW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, ASTH is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check IMACW's competition here
ASTH vs CCM Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, CCM has a market cap of 690.2K. Regarding current trading prices, ASTH is priced at $38.38, while CCM trades at $4.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas CCM's P/E ratio is -1.51. In terms of profitability, ASTH's ROE is +0.04%, compared to CCM's ROE of +0.07%. Regarding short-term risk, ASTH is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check CCM's competition here
ASTH vs MNDR Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, MNDR has a market cap of 603.6K. Regarding current trading prices, ASTH is priced at $38.38, while MNDR trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas MNDR's P/E ratio is -0.28. In terms of profitability, ASTH's ROE is +0.04%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, ASTH is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check MNDR's competition here
ASTH vs NIVF Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, NIVF has a market cap of 397.9K. Regarding current trading prices, ASTH is priced at $38.38, while NIVF trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas NIVF's P/E ratio is 0.02. In terms of profitability, ASTH's ROE is +0.04%, compared to NIVF's ROE of +0.33%. Regarding short-term risk, ASTH is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check NIVF's competition here
ASTH vs NIVFW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, NIVFW has a market cap of 64.8K. Regarding current trading prices, ASTH is priced at $38.38, while NIVFW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas NIVFW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, ASTH is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check NIVFW's competition here
ASTH vs DVCR Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas DVCR's P/E ratio is 28.34. In terms of profitability, ASTH's ROE is +0.04%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, ASTH is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check DVCR's competition here
ASTH vs SLHGP Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, ASTH's ROE is +0.04%, compared to SLHGP's ROE of -0.48%. Regarding short-term risk, ASTH is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check SLHGP's competition here
ASTH vs DCGOW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas DCGOW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to DCGOW's ROE of -0.89%. Regarding short-term risk, ASTH is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check DCGOW's competition here
ASTH vs HNGR Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas HNGR's P/E ratio is 19.71. In terms of profitability, ASTH's ROE is +0.04%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, ASTH is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check HNGR's competition here
ASTH vs SLHG Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas SLHG's P/E ratio is -1.48. In terms of profitability, ASTH's ROE is +0.04%, compared to SLHG's ROE of N/A. Regarding short-term risk, ASTH is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check SLHG's competition here
ASTH vs TVTY Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas TVTY's P/E ratio is 19.06. In terms of profitability, ASTH's ROE is +0.04%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, ASTH is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check TVTY's competition here
ASTH vs ATIP-WT Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, ASTH is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check ATIP-WT's competition here
ASTH vs AFAM Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas AFAM's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, ASTH is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check AFAM's competition here
ASTH vs KND Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, KND has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas KND's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to KND's ROE of -0.53%. Regarding short-term risk, ASTH is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check KND's competition here
ASTH vs NFH Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, NFH has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas NFH's P/E ratio is -19.75. In terms of profitability, ASTH's ROE is +0.04%, compared to NFH's ROE of -0.06%. Regarding short-term risk, ASTH is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check NFH's competition here
ASTH vs TLMD Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas TLMD's P/E ratio is -1.60. In terms of profitability, ASTH's ROE is +0.04%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, ASTH is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for ASTH.Check TLMD's competition here
ASTH vs TLMDW Comparison June 2026
ASTH plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ASTH stands at 1.9B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, ASTH is priced at $38.38, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ASTH currently has a P/E ratio of 62.92, whereas TLMDW's P/E ratio is N/A. In terms of profitability, ASTH's ROE is +0.04%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, ASTH is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for ASTH.Check TLMDW's competition here